January 16, 2024
Effective February 1, 2024, Medi-Cal Rx will require prior authorization (PA) for Reyvow (lasmiditan succinate), which is used to treat migraines. PAs will be required for new and renewing prescriptions.
Alternatives not requiring a PA request are listed on the Medi-Cal Rx Contract Drugs List and include:
- Imitrex (sumatriptan)
- Amerge (naratriptan)
- Maxalt and Maxalt-MLT (rizatriptan)
- Nurtec ODT (rimegepant)
- Ubrelvy (ubrogepant)
- Ergotamine/caffeine
For more information, see the announcement.
Questions? Contact the Medi-Cal Rx Customer Service Center (CSC) at (800) 977-2273 or MediCalRxEducationOutreach@magellanhealth.com.